News & Updates

Using small molecule drugs to modulate the cystic fibrosis transmembrane conductance regulator (CFTR) protein improves multiple aspects of cystic fibrosis in paediatric patients, including lung function, CFTR protein function, and nutritional status, according to a recent meta-analysis.

In the treatment of children with obstructive sleep apnoea syndrome (OSAS), use of intranasal corticosteroids falls short of producing substantial changes in symptoms as well as in polysomnographic and neurobehavioural parameters at 3 and 12 months, a study has found.

The KRAS^G12C inhibitor adagrasib shows durable clinical benefit, without new safety signals, in pretreated patients with advanced non–small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation in the KRYSTAL-1 trial.

Use of 2.5-mg tissue plasminogen activator (tPA) and 5-mg deoxyribonuclease (DNase) therapy as a starting intrapleural dose, with up-titration if needed, appears effective in patients with pleural infection, suggests a study, noting that this treatment warrants further research.